Vanguard Group Inc. raised its position in Protagonist Therapeutics Inc (NASDAQ:PTGX) by 3.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 325,395 shares of the company’s stock after acquiring an additional 11,881 shares during the quarter. Vanguard Group Inc. owned approximately 1.93% of Protagonist Therapeutics worth $3,680,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp grew its position in Protagonist Therapeutics by 5.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 27,626 shares of the company’s stock valued at $313,000 after acquiring an additional 1,478 shares in the last quarter. Teachers Advisors LLC grew its position in Protagonist Therapeutics by 71.4% in the 2nd quarter. Teachers Advisors LLC now owns 16,218 shares of the company’s stock valued at $183,000 after acquiring an additional 6,757 shares in the last quarter. TIAA CREF Investment Management LLC grew its position in Protagonist Therapeutics by 19.5% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 23,372 shares of the company’s stock valued at $264,000 after acquiring an additional 3,812 shares in the last quarter. Rhumbline Advisers acquired a new position in Protagonist Therapeutics in the 2nd quarter valued at about $114,000. Finally, Northern Trust Corp grew its position in Protagonist Therapeutics by 24.0% in the 2nd quarter. Northern Trust Corp now owns 98,825 shares of the company’s stock valued at $1,118,000 after acquiring an additional 19,159 shares in the last quarter. 39.68% of the stock is owned by institutional investors.
Protagonist Therapeutics Inc (PTGX) opened at $19.25 on Monday. Protagonist Therapeutics Inc has a 52-week low of $8.00 and a 52-week high of $26.36.
Several equities analysts have weighed in on the company. Zacks Investment Research raised Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a research report on Saturday, November 11th. ValuEngine downgraded Protagonist Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 11th. Finally, BMO Capital Markets dropped their target price on Protagonist Therapeutics from $45.00 to $40.00 and set an “outperform” rating for the company in a research report on Thursday, October 19th.
In other news, insider Richard S. Shames sold 2,017 shares of Protagonist Therapeutics stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $19.00, for a total value of $38,323.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider David Y. Liu sold 7,000 shares of Protagonist Therapeutics stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $16.97, for a total value of $118,790.00. The disclosure for this sale can be found here. Insiders sold a total of 13,579 shares of company stock valued at $227,374 in the last quarter. Company insiders own 15.50% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.com-unik.info/2017/12/04/vanguard-group-inc-grows-holdings-in-protagonist-therapeutics-inc-ptgx.html.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
What are top analysts saying about Protagonist Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Protagonist Therapeutics Inc and related companies.